UNSPSC 51434803: Ciheptolane

This classification denotes an antihypertensive agent and analgesic agent with the molecular formula C20H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NLD2X0VD2U, chemically known as 10,11-dihydro-n,n-dimethylspiro(5h-dibenzo(a,d)cycloheptene-5,2-(1,3)dioxolane)-4-methylamine. but generally known as ciheptolane, which bears US NIH Compound Identifier 115697. European Medicines Agency schedules Ciheptolane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06261MIG.

UNSPSC 51434803 Ciheptolane, a Commodity code, does not align with the recent state and local contract opportunities tagged under it. The three most recent solicitations—from the City of Tampa, Texas Health and Human Services Commission, and Minnesota Multistate Cooperative Purchasing Alliance—are all procurement vehicles for pharmaceutical supply and pharmacy benefit management services, including advanced life support medications, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs. None of these opportunities reference ciheptolane specifically or solicit this particular active pharmaceutical ingredient. The code shows minimal relevant recent activity and appears to be either misclassified in these postings or rarely used for state and local procurement.

State and local governments are instead buying broader pharmaceutical supply contracts, emergency medications for fire rescue operations, and cooperative purchasing arrangements across multiple jurisdictions. The City of Tampa's sealed-bid solicitation (26P00188, due April 8, 2026, estimated value $40,000.00) targets four specific medication line items for Tampa Fire Rescue. The MMCAP RFP (S1070000015802, due March 26, 2026) establishes multiple-award contracts for generic pharmaceuticals and OTC products across Minnesota and participating states through three authorized wholesalers. The Texas HHS Commission's exploratory RFI (HHS0017013, issued April 3, 2026) seeks vendor capabilities for direct manufacturer contracting outside traditional pharmacy benefit manager channels. The code does not appear to support meaningful procurement activity under its stated commodity definition, and business development professionals should verify the accurate UNSPSC classification before committing resources to pursue opportunities under this code.